Our study, utilizing NGS analysis of CTC-derived RNA collected serially from patients with HCC during Atezo+Bev therapy, showed that changes in TGF-β signaling and apoptotic signaling pathways were correlated with treatment response. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.